2seventy bio develops immuno-oncology cell therapies that utilize engineered T cells to target and eliminate cancer cells. The company aims to extend patients' lives by providing effective treatment options that address the limitations of current cancer therapies.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often have limitations, leading to insufficient treatment outcomes and reduced lifespan for patients. There is a need for more effective and targeted approaches to eliminate cancer cells and improve patient survival rates.
Solution
2seventy bio develops immuno-oncology cell therapies using engineered T cells designed to specifically target and eradicate cancer cells. By leveraging gene and cell therapy expertise, the company aims to provide patients with innovative treatment options that overcome the shortcomings of existing cancer treatments. The company focuses on outmaneuvering cancer to give patients the opportunity for more time with their loved ones, pursuing their passions, and living their lives to the fullest.
Target Audience
The primary target audience includes cancer patients seeking more effective treatment options and healthcare providers specializing in oncology and cell therapy.
Features
- Engineered T-cell therapies for targeted cancer cell elimination
- Immuno-oncology approach to harness the body's immune system
- Development of innovative treatment options to address limitations of current therapies